ANCA-associated vasculitis (AAV) patients treated with rituximab are up to four times more likely to develop hypogammaglobulinemia (HGG),…
Articles by Andrea Lobo, PhD
Treatment with rituximab is superior to cyclophosphamide at inducing disease remission in people with granulomatosis with polyangiitis (GPA),…
About a quarter of people with granulomatosis with polyangiitis (GPA)Â or microscopic polyangiitis (MPA) under maintenance treatment with rituximab experience…
People with ANCA-associated vasculitis (AAV) have an 83% higher risk of developing cardiovascular and cerebrovascular diseases (CCVD) relative to…
Researchers have identified a set of clinical red flags that could help detect eosinophilic granulomatosis with polyangiitis (EGPA), the rarest…
Eye symptoms related to ANCA-associated vasculitis (AAV) are most common among those with granulomatosis with polyangiitis (GPA), affecting more…
Adding Tavneos (avacopan) to standard maintenance treatment safely and effectively promotes disease remission in ANCA-associated vasculitis (AAV) patients,…
Using benralizumab — a medication approved in the U.S. for a rare type of asthma — off-label as an add-on…
ANCA-associated vasculitis (AAV) patients with neurological manifestations are more than three times more likely to have large blood vessel…
While it’s rare in children, ANCA-associated vasculitis (AAV)-related glomerulonephritis, that is, an inflammation of the glomeruli, the kidneys’ filtering…